Business briefs: Pfizer, physicians and ACOs

Share this article:

The US Patent and Trademark Office has extended the life of Pfizer's Celebrex patent through December 2, 2015, reported Dow Jones. The agency gave the drug an additional 18 months of patent life by overturning a 2008 federal appeals court finding that rendered the patent invalid. Dow Jones reported that analysts had forecast a sales drop of $1.85 billion after the drug's initial patent expiration date of May 30, 2014 kicked in.

A recent survey by SurveyHealthCare indicated that 40% of doctors could not describe an Accountable Care Organization. The survey defined an ACO as an organization of HCPs that “agrees to be accountable for the quality, cost, and overall care of patients who are assigned to it”. The Affordable Care Act provides incentives to ACO's when they save money, but still provide quality treatment. Of the 508 physician respondents, 60% said they could describe an ACO, 17% already work for an ACO, more than half say they have influence in purchasing decisions, 13% have a “specific title” which is associated with that purchasing power and 50% have positive feelings about ACOs while the other 50% responded negatively.

 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.